These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan. Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977 [TBL] [Abstract][Full Text] [Related]
5. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329 [TBL] [Abstract][Full Text] [Related]
6. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Heinz WJ; Cabanillas Stanchi KM; Klinker H; Blume O; Feucht J; Hartmann U; Feuchtinger T; Lang P; Handgretinger R; Döring M Med Mycol; 2016 Feb; 54(2):128-37. PubMed ID: 26483433 [TBL] [Abstract][Full Text] [Related]
7. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530 [TBL] [Abstract][Full Text] [Related]
8. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Crombag MR; Huisman C; Kemper EM; Brüggemann RJ; Bijleveld YA Ther Drug Monit; 2012 Jun; 34(3):320-5. PubMed ID: 22561586 [TBL] [Abstract][Full Text] [Related]
11. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068 [TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial. Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343 [TBL] [Abstract][Full Text] [Related]
19. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761 [TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]